Have a feature idea you'd love to see implemented?
Let us know!
HOWL Werewolf Therapeutics Inc
Price (delayed)
$1.78
Market cap
$79.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.5
Enterprise value
-$6.73M
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its
Highlights
Werewolf Therapeutics's debt has decreased by 30% YoY
The quick ratio has declined by 17% since the previous quarter but it has increased by 5% year-on-year
The gross profit has plunged by 87% YoY and by 64% from the previous quarter
Werewolf Therapeutics's revenue has plunged by 87% YoY and by 64% from the previous quarter
Key stats
What are the main financial stats of HOWL
Market
Valuations
Earnings
Shares outstanding
44.56M
Market cap
$79.32M
Enterprise value
-$6.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.87
Price to sales (P/S)
22.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.99
Revenue
$3.39M
EBIT
-$55.59M
EBITDA
-$52.69M
Free cash flow
-$46.85M
Per share
Balance sheet
Liquidity
EPS
-$1.5
Free cash flow per share
-$1.07
Book value per share
$2.05
Revenue per share
$0.08
TBVPS
$3.2
Total assets
$140.04M
Total liabilities
$50.66M
Debt
$36.78M
Equity
$89.38M
Working capital
$113.37M
Debt to equity
0.41
Current ratio
10.1
Quick ratio
9.89
Net debt/EBITDA
1.63
Margins
Efficiency
Dividend
EBITDA margin
-1,556%
Gross margin
100%
Net margin
-1,834.6%
Operating margin
-1,955.3%
Return on assets
-38.5%
Return on equity
-58.8%
Return on invested capital
-98.1%
Return on capital employed
-43.6%
Return on sales
-1,641.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HOWL stock price
How has the Werewolf Therapeutics stock price performed over time
Intraday
8.54%
1 week
-7.77%
1 month
-37.54%
1 year
-24.89%
YTD
-53.89%
QTD
-16.04%
Financial performance
How have Werewolf Therapeutics's revenue and profit performed over time
Revenue
$3.39M
Gross profit
$3.39M
Operating income
-$66.21M
Net income
-$62.12M
Gross margin
100%
Net margin
-1,834.6%
The gross profit has plunged by 87% YoY and by 64% from the previous quarter
Werewolf Therapeutics's revenue has plunged by 87% YoY and by 64% from the previous quarter
The company's net income has shrunk by 67% YoY and by 16% QoQ
Werewolf Therapeutics's operating income has shrunk by 63% YoY and by 13% QoQ
Growth
What is Werewolf Therapeutics's growth rate over time
Valuation
What is Werewolf Therapeutics stock price valuation
P/E
N/A
P/B
0.87
P/S
22.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.99
HOWL's EPS is down by 38% YoY and by 11% from the previous quarter
HOWL's price to book (P/B) is 38% lower than its last 4 quarters average of 1.4
The equity has contracted by 21% YoY and by 14% from the previous quarter
Werewolf Therapeutics's revenue has plunged by 87% YoY and by 64% from the previous quarter
HOWL's price to sales (P/S) is 47% higher than its last 4 quarters average of 15.6
Efficiency
How efficient is Werewolf Therapeutics business performance
Werewolf Therapeutics's return on equity has shrunk by 87% YoY and by 22% QoQ
Werewolf Therapeutics's return on assets has shrunk by 85% YoY and by 22% QoQ
HOWL's ROIC has shrunk by 59% YoY and by 39% QoQ
Dividends
What is HOWL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HOWL.
Financial health
How did Werewolf Therapeutics financials performed over time
The total assets is 176% higher than the total liabilities
The company's total liabilities fell by 21% YoY
The total assets is down by 21% YoY and by 9% QoQ
Werewolf Therapeutics's debt is 59% lower than its equity
Werewolf Therapeutics's debt has decreased by 30% YoY
The equity has contracted by 21% YoY and by 14% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.